News
PEN
223.18
-1.41%
-3.20
Inari Medical: Buy On Growing TAM
Inari Medical, Inc.'s share price has dropped due to a Department of Justice investigation on doctor payment practices. Inari is the leader in the treatment of venous thromboembolism. The company has a strong growth rate and is coming out with new products to grow their TAM. The medical device company has high potential operating margins and strong growth. NARI is one of the top medical device stocks to own for 2024.
Seeking Alpha · 1d ago
J&J-Shockwave deal makes strategic sense: analysts
Johnson & Johnson in talks to acquire cardiac device maker Shockwave Medical, Wall Street Journal reports. The company's stock rose 10% on Tuesday amid reports of a potential deal. Wells Fargo analysts say a potential J&J-Shockwave deal makes strategic sense. Bank of America says a deal would be a strategic fit for JNJ.
Seeking Alpha · 1d ago
PEN July 2025 Options Begin Trading
NASDAQ · 2d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 3d ago
Weekly Report: what happened at PEN last week (0318-0322)?
Weekly Report · 3d ago
Notable Friday Option Activity: PEN, PRGS, ULTA
NASDAQ · 6d ago
Penumbra Stock: A Deep Dive Into Analyst Perspectives (8 Ratings)
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. The company has an average 12-month price target of $281.5. In the last three months, 8 analysts have released ratings for Penumbra. Analysts have decreased the average price target by 1.34%.
Benzinga · 6d ago
Penumbra Is Maintained at Buy by Truist Securities
Dow Jones · 6d ago
Penumbra Price Target Cut to $280.00/Share From $290.00 by Truist Securities
Dow Jones · 6d ago
Truist Securities Maintains Buy on Penumbra, Lowers Price Target to $280
Benzinga · 6d ago
Estimating The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)
Penumbra, Inc. (NYSE:PEN) is estimated to have a fair value of US$216 based on 2 Stage Free Cash Flow to Equity. Penumbra's current share price of US $236 suggests the company is potentially trading close to its fair value. We will use the Discounted Cash Flow (DCF) model to estimate the value of the company. The model is based on the company's future cash flows and is discounted to today's value.
Simply Wall St · 03/21 14:55
Positive Outlook for Penumbra: Accelerated THUNDER Trial Progress and Thunderbolt System Potential Justify Buy Rating
TipRanks · 03/19 10:16
Weekly Report: what happened at PEN last week (0311-0315)?
Weekly Report · 03/18 09:26
Weekly Report: what happened at PEN last week (0304-0308)?
Weekly Report · 03/11 09:26
Penumbra’s Growth Trajectory and Market Dominance Reinforce Buy Rating
TipRanks · 03/04 13:15
Weekly Report: what happened at PEN last week (0226-0301)?
Weekly Report · 03/04 09:27
Piper Sandler cuts Inari to neutral; cites slowing growth, DOJ probe
Seeking Alpha · 03/01 21:03
Analysts Offer Insights on Healthcare Companies: Penumbra (PEN), Jazz Pharmaceuticals (JAZZ) and Argenx Se (ARGX)
TipRanks · 03/01 10:04
Penumbra Q4: Solid Is Not Good Enough
Penumbra, Inc. Focuses on removing clots and treating aneurysms in the neurovascular market. The company reported a 29% increase in sales in the fourth quarter. Despite solid growth and operating leverage, Penumbra valuations remain high as slower growth raises concerns.
Seeking Alpha · 02/26 20:55
Weekly Report: what happened at PEN last week (0219-0223)?
Weekly Report · 02/26 09:28
More
Webull provides a variety of real-time PEN stock news. You can receive the latest news about Penumbra Inc through multiple platforms. This information may help you make smarter investment decisions.
About PEN
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.